Section Review—Central & Peripheral Nervous Systems: Tachykinin Antagonists in Development

Abstract

The literature on tachykinin antagonists published during the second semester of 1994 is reviewed with emphasis on the potential clinical indications for antagonists of the three neurokinin receptor families, namely NK₁, NK₂ and NK₃ . For each therapeutic domain, particular attention is given to the development of adequate experimental animal models needed to evaluate new compounds in vitro and in vivo. Finally, recent developments in the molecular biology of NK₁ receptors and design of new non-peptide NK₁ antagonists are presented.